SCHEMBL4772252

SCHEMBL4772252

CCCC[Sn](CCCC)(CCCC)c1ccc(CC(C)=O)cc1

nearest known ligand 0.43

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.43
HPGD P15428 2/20 0.43
HSD17B10 Q99714 1/20 0.43
POLB P06746 2/20 0.41
KDM4E B2RXH2 1/20 0.37
CYP1A2 P05177 1/20 0.37
CYP2D6 P10635 1/20 0.37
PDE4A P27815 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
HIF1A Q16665 1/20 0.37
HDAC10 Q969S8 1/20 0.37
HDAC6 Q9UBN7 1/20 0.37
THRA P10827 1/20 0.34
THRB P10828 1/20 0.34
LMNA P02545 1/20 0.34
RARB P10826 1/20 0.33
PLA2G4B P0C869 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7489132 0.86 ALDH1A1 (0.61) ALDH1A1HPGDHSD17B10THRATHRB
SCHEMBL4774135 0.83 ALDH1A1 (0.49) ALDH1A1HPGDHSD17B10POLBKDM4E
SCHEMBL1983658 0.79 TSHR (0.32) CYP1A2CYP2D6THRBLMNA
SCHEMBL28435445 0.79 KMT2A (0.44) HPGDHSD17B10POLBSMN1; SMN2LMNA
SCHEMBL2701941 0.78 TSHR (0.34) ALDH1A1HPGDHSD17B10KDM4EHIF1A
SCHEMBL154543 0.77 TP53 (0.37) ALDH1A1HSD17B10KDM4ESMN1; SMN2HIF1A
SCHEMBL8906499 0.77 FFAR1 (0.50) ALDH1A1HPGDHSD17B10LMNA
SCHEMBL6288870 0.77 BDKRB2 (0.44) ALDH1A1HPGDLMNA
SCHEMBL11271830 0.76 ALDH1A1 (0.71) ALDH1A1HPGDHSD17B10POLBKDM4E
SCHEMBL2480571 0.75 RARB (0.50) ALDH1A1RARBPLA2G4B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1020445-B1 FUSED PYRIDINE DERIVATIVES EISAI R&D MAN CO LTD (JP) 2008-08-13 EP disclosed
US-6875761-B2 Certain 1,3-disubstituted isoquinoline derivatives EISAI CO., LTD. (JP) 2005-04-05 US disclosed
US-20040204421-A1 Certain 1,3-disubstituted isoquinoline derivatives EISAI CO., LTD. 2004-10-14 US disclosed
US-6790844-B2 MUSCLE RELAXANTS; ANTISEROTONINE AGENT EISAI CO., LTD (JP) 2004-09-14 US disclosed
US-20020013460-A1 Condensed pyridine compound EISAI CO., LTD 2002-01-31 US disclosed
US-6340759-B1 ANTISPASMODIC AGENTS EISAI CO., LTD. (JP) 2002-01-22 US disclosed
EP-1020445-A1 FUSED PYRIDINE DERIVATIVES Eisai Co., Ltd. (JP) 2000-07-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020013460-A1 Condensed pyridine compound MUSK, HTR1A, PAX3 ALDH1A1 2989/4885HPGD 1216/4885HSD17B10 3854/4885
US-20040204421-A1 Certain 1,3-disubstituted isoquinoline derivatives MUSK, HTR1A, RYR1 ALDH1A1 1071/4885HPGD 1548/4885HSD17B10 3472/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.